Cardiometabolic RNA and next-generation lipid drug trial starts vs Alzheimer's disease drug trial starts

In 2025, cardiometabolic RNA and next-generation lipid drug trial starts worldwide stood at 30, against 78 for alzheimer's disease drug trial starts.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Cardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts

Unit: count · 12 observations

2 series · one axis
Cardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts: GlobalCardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Cardiometabolic RNA and next-generation lipid drug trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 6 to 87. Latest values: Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 20 40 60 80 100 2020 2021 2022 2023 2024 2025 30 78 Cardiometabolic RNA and next-generation lipid drug trial starts Alzheimer's disease drug trial starts
Cardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts: GlobalCardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Cardiometabolic RNA and next-generation lipid drug trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 6 to 87. Latest values: Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 30 60 90 2020 2021 2022 2023 2024 2025 30 78 Cardiometabolic RNA and next-generation lipid drug trial starts Alzheimer's disease drug trial starts
Cardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts: GlobalCardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Cardiometabolic RNA and next-generation lipid drug trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 6 to 87. Latest values: Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 30 60 90 2020 2021 2022 2023 2024 2025 30 78 Cardiometabolic RNA and next-generation lipid drug trial starts Alzheimer's disease drug trial starts
View the underlying data
Cardiometabolic RNA and next-generation lipid drug trial starts and Alzheimer's disease drug trial starts: Global
Indicator Period Type Value
Cardiometabolic RNA and next-generation lipid drug trial starts 2025 Actual 30
Cardiometabolic RNA and next-generation lipid drug trial starts 2024 Actual 51
Cardiometabolic RNA and next-generation lipid drug trial starts 2023 Actual 22
Cardiometabolic RNA and next-generation lipid drug trial starts 2022 Actual 32
Cardiometabolic RNA and next-generation lipid drug trial starts 2021 Actual 28
Cardiometabolic RNA and next-generation lipid drug trial starts 2020 Actual 6
Alzheimer's disease drug trial starts 2025 Actual 78
Alzheimer's disease drug trial starts 2024 Actual 71
Alzheimer's disease drug trial starts 2023 Actual 58
Alzheimer's disease drug trial starts 2022 Actual 81
Alzheimer's disease drug trial starts 2021 Actual 87
Alzheimer's disease drug trial starts 2020 Actual 66

Shared periods

Side by side

6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Cardiometabolic RNA and next-generation lipid drug trial starts Alzheimer's disease drug trial starts
2020 6 ClinicalTrials.gov 66 ClinicalTrials.gov
2021 28 ClinicalTrials.gov 87 ClinicalTrials.gov
2022 32 ClinicalTrials.gov 81 ClinicalTrials.gov
2023 22 ClinicalTrials.gov 58 ClinicalTrials.gov
2024 51 ClinicalTrials.gov 71 ClinicalTrials.gov
2025 30 ClinicalTrials.gov 78 ClinicalTrials.gov

Provenance

Where these numbers come from

Cardiometabolic RNA and next-generation lipid drug trial starts

Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Alzheimer's disease drug trial starts

Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related